Payment overview · 2025
General Payments
$538.44
26 reported records · 11 companies
Healthcare provider profile · identity verified
Robert C Masterson, DO
Allopathic & Osteopathic Physicians|Family Medicine · VICKSBURG, MS · NPI 1053358853
Verified facts
What the public records show
CMS Open Payments records show Robert C Masterson, DO received $538.44 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.49 | 21.8% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $111.05 | 20.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.99 | 20.6% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $42.27 | 7.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.67 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.18 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.77 | 4.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.56 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.70 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.57 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.44 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.49 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $111.05 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $95.78 | 6 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $42.27 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 467 | 118 |
| Metformin Hcl | Metformin Hcl | 332 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 61 |
| Omeprazole | Omeprazole | 238 | 72 |
| Glimepiride | Glimepiride | 212 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 50 |
| Lisinopril | Lisinopril | 148 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 41 |
| Potassium Chloride | Potassium Chloride | 137 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 18 |
| Meloxicam | Meloxicam | 134 | 40 |
| Gabapentin | Gabapentin | 132 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 35 |
| Furosemide | Furosemide | 129 | 43 |
| Ozempic | Semaglutide | 122 | 18 |
| Simvastatin | Simvastatin | 122 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 30 |
| Lovastatin | Lovastatin | 93 | 24 |
| Azithromycin | Azithromycin | 91 | 70 |
| Losartan Potassium | Losartan Potassium | 89 | 24 |
| Celecoxib | Celecoxib | 83 | 21 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 28 |
| Chlorthalidone | Chlorthalidone | 72 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 68 | 11 |
| Pregabalin | Pregabalin | 67 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 50 |
| Famotidine | Famotidine | 64 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 26 |
| Mounjaro | Tirzepatide | 55 | 12 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Temazepam | Temazepam | 46 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 18 |
| Allopurinol | Allopurinol | 43 | 15 |
| Jardiance | Empagliflozin | 43 | 11 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Telmisartan | Telmisartan | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 31 |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 18 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Prednisone | Prednisone | 31 | 25 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Eliquis | Apixaban | 28 | 12 |
| Estradiol | Estradiol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Mupirocin | Mupirocin | 21 | 14 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Clarithromycin | Clarithromycin | 18 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Efavirenz | Efavirenz | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 11 |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.44 · 26 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CLOTTRIEVER BOLD CATHETER, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, INSPIRE, PREVNAR 20, VOQUEZNA, VRAYLAR, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error